Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

FDA proposal on GLP-1 503B compounding and Q1 earnings preview

Sources (1)

The FDA has proposed removing the three main GLP-1 molecules from the 503B compounding list, and the market reaction has overstated the hit to HIMS. HIMS mainly operates through the 503A route and has already completed its strategic shift to branded drugs, so its actual reliance on 503B is minimal. A clear-out of competitors may even work in its favour.

Competitive impact

HIMS angle

Has locked in branded-drug partnerships with Novo and Lilly and may benefit from rivals being cleared out

Seeking Alpha view

A Seeking Alpha analysis of 1 May argues the rule may actually help HIMS, as the competitive landscape concentrates in leading platforms with established brand partnerships

True victims

Small telehealth companies that rely on 503B outsourcing facilities for large-scale compounding

FDA 503B proposal

Action

The FDA has formally proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list

Date

30 Apr 2026

Final decision

After the public comment period ends

Public comment deadline

29 Jun 2026

Reason

There is no clinical need for outsourcing facilities to compound these drugs in bulk

Key insights

  • 503B is the large-scale bulk production route for outsourcing facilities (no individual prescription needed)
  • 503A is the individualised compounding route for licensed doctors and pharmacists (individual prescription needed, regulated state by state)
  • HIMS mainly uses the 503A route, not 503B
  • A researcher at the consultancy Avalere Health said explicitly that the 503B list exclusion may not affect how current GLP-1 compounded drugs actually operate (quoted by NBC News)
  • HIMS has already completed its strategic shift from compounded drugs to distributing branded drugs (the Novo and Lilly partnerships are both in place), so its reliance on 503B is minimal

Price action

Price

$27.39 (close on 2 May 2026)

Pullback

About 12% below the $31 high

Q1 earnings preview

Date

11 May 2026, after the close

EPS consensus

$0.06 (down 70% year on year)

Revenue consensus

$621 million (up 6% year on year)

Sources 1

  1. NBC News, Seeking Alpha (1 May 2026), FDA official proposal notice (30 Apr 2026)

A brief is a lead for our research, not a verified conclusion or advice.